Raymond James Financial
IBRX icon

Raymond James Financial’s ImmunityBio IBRX Stock Holding History

Raymond James Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Sell
360,272
-15,429
-4% -$117K ﹤0.01% 3129
2026
Q1 		$2.88M Buy
375,701
+164,466
+78% +$1.13M ﹤0.01% 3058
2025
Q4 		$418K Sell
211,235
-28,262
-12% -$64K ﹤0.01% 4381
2025
Q3 		$589K Buy
239,497
+86,437
+56% +$223K ﹤0.01% 4015
2025
Q2 		$404K Buy
153,060
+68,956
+82% +$185K ﹤0.01% 4129
2025
Q1 		$253K Buy
84,104
+16,750
+25% +$50.8K ﹤0.01% 4301
2024
Q4 		$172K Buy
+67,354
New +$281K ﹤0.01% 4435

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's IBRX Position: Q2 2026 in Review

Raymond James Financial reduced its ImmunityBio (IBRX) stake by 4.1% in Q2 2026, selling an estimated $117K and leaving 360,272 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3129.

Raymond James Financial first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Raymond James Financial held 360,272 shares of ImmunityBio worth $3.15M as of Q2 2026.
  • Raymond James Financial sold 15,429 ImmunityBio shares in Q2 2026, an estimated $117K.
  • ImmunityBio made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3129 holding.
  • Raymond James Financial first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.